A new surgical approach for fertility-sparing management of diffuse endometrial G2 endometrioid adenocarcinoma: a step-by-step technique.
U Catena, M Mirandola, F M Capomacchia...
https://pubmed.ncbi.nlm.nih.gov/37010338/Actively Recruiting
Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2025-07-22
100
Participants Needed
1
Research Sites
29 weeks
Total Duration
Researchers are evaluating the obstetric and oncological outcomes in women diagnosed with endometrial adenocarcinoma EAC or atypical endometrial hyperplasia AEH who received conservative treatment. This observational, single-center study takes place at the CLASS Hysteroscopy Center in Rome and focuses on patients treated either to preserve fertility or due to medical reasons preventing standard radical surgery. The treatment involves hysteroscopic removal of lesions using a 15 Fr mini-resectoscope, sometimes combined with visual dilation and curettage techniques. After surgery, a 52 mg levonorgestrel-releasing intrauterine device LNG-IUD is placed. In certain cases, especially for patients with higher-grade cancer or poor prognostic markers, oral progestin therapy with Megestrol Acetate is added. Follow-up includes hysteroscopic biopsies at 3, 6, and 12 months. Participants will be monitored for pregnancy rates, miscarriage rates, and live birth rates within 12 months following a confirmed complete response. Researchers will also assess the disease-free interval for up to 12 months after treatment. The total follow-up lasts one year, with periodic biopsies to evaluate treatment response and ongoing health.
CONDITIONS
Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment
U
URSULA CATENA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Single procedure with immediate post-operative care
Participants undergo hysteroscopic resection of the endometrial lesion and insertion of a levonorgestrel-releasing intrauterine device (LNG-IUD). Some participants may also receive oral progestin therapy with Megestrol Acetate depending on their condition.
1 visit (in-person) for the procedure
Duration - Up to 12 months
Participants are monitored with hysteroscopic endometrial biopsies to assess treatment response and disease status.
Visits at 3, 6, and 12 months (in-person)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
U Catena, M Mirandola, F M Capomacchia...
https://pubmed.ncbi.nlm.nih.gov/37010338/Philippe Morice, Alexandra Leary, Carien Creutzberg...
https://pubmed.ncbi.nlm.nih.gov/26354523/Yong-Tark Jeon, In-Ae Park, Yong-Beom Kim...
https://pubmed.ncbi.nlm.nih.gov/16168561/Attilio Di Spiezio Sardo, Maria Chiara De Angelis, Luigi Della Corte...
https://pubmed.ncbi.nlm.nih.gov/32467056/Hyuna Sung, Jacques Ferlay, Rebecca L Siegel...
https://pubmed.ncbi.nlm.nih.gov/33538338/Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead Sponsor